10-K/A: Xenetic Biosciences Files Amended 10-K to Include Part III Information

Xenetic Biosciences files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive officers, compensation, and related matters.

Summary

• Xenetic Biosciences filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2024.
• The amendment includes information required by Items 10 through 14 of Part III of Form 10-K, which was initially omitted in reliance on General Instruction G(3).
• The company's definitive proxy statement will be filed later this year, prompting the inclusion of Part III information in this amendment.
• Part III of the original filing is amended and restated in its entirety by this amendment.
• The amendment also includes updated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• The cover page is updated to reflect the number of outstanding shares of common stock as of April 18, 2025, which is 1,542,139.
• The aggregate market value of voting and non-voting common stock held by non-affiliates as of June 28, 2024, was approximately $5,301,818.
• James Parslow serves as the Interim Chief Executive Officer, Chief Financial Officer, and Corporate Secretary.
• The Board of Directors consists of several members with diverse backgrounds in life sciences, finance, and business development.
• The Board has three standing committees: Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
• The Audit Committee is composed of Mr. Dastoor (chair), Dr. Borisenko and Dr. Vinogradov.
• The Board has determined that all current members of the Audit Committee are independent.
• The company has adopted a Code of Business Conduct and Ethics applicable to all employees, officers, and directors.
• During 2024, all Section 16(a) filing requirements applicable to the company's executive officers, directors and greater than 10% beneficial owners were complied with, except for the initial Form 3 filing by Dr. Genkin.
• The company provides a 401(k) plan with a matching contribution of 100% up to 4% of an employee's salary.
• The Compensation Actually Paid to our CEO and the average of Compensation Actually Paid to our Non-CEO NEOs increased in 2024, which corresponded to the increase in the Company's TSR and decrease in Net Loss in 2024.
• The Compensation Actually Paid for both our former CEO and Non-CEO NEOs in 2024 increased primarily due to severance commitments incurred in 2024.
• The company has agreements with PeriNess Ltd. for clinical trial services and with Dr. Genkin for consulting services related to the DNase-based oncology program.
• The Board has determined that several directors are independent, including Dr. Callaway, Mr. Dastoor, Dr. Kornberg, Mr. Logal, Mr. Mizrahy (until October 2024), Dr. Vinogradov and Dr. Borisenko.
• Marcum LLP billed $165,000 in audit fees and audit-related fees to the company for the fiscal year ended December 31, 2024.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with some neutral to slightly positive elements related to corporate governance and executive compensation. However, the presence of related party transactions and the need for an amended filing introduce some uncertainty.

Positives

• The company has an Audit Committee comprised of independent directors.
• The company offers a 401(k) plan with a matching contribution.
• The company has a Code of Business Conduct and Ethics.
• The Compensation Actually Paid to our CEO and the average of Compensation Actually Paid to our Non-CEO NEOs increased in 2024, which corresponded to the increase in the Company's TSR and decrease in Net Loss in 2024.

Negatives

• Dr. Genkin has not yet filed the initial Form 3 since his election to the Board.
• The Compensation Actually Paid for both our former CEO and Non-CEO NEOs in 2024 increased primarily due to severance commitments incurred in 2024.

Risks

• Related party transactions, such as those with Pharmsynthez and Peri-Ness Technologies, could present potential conflicts of interest.
• The company's dependence on key personnel, such as the Interim CEO and board members, could pose a risk if they were to leave or become unavailable.
• The company's reliance on collaborative agreements, such as the one with Pharmsynthez, could be impacted if the partners fail to meet their obligations or if the agreements are terminated.

Future Outlook

Pharmsynthez is currently determining next steps regarding a gap mitigation strategy for its Epolong registration dossier in Russia.

Industry Context

The document provides insight into the corporate governance, executive compensation, and related party transactions of a biotechnology company, which is relevant for understanding the company's operations and potential risks within the biotech industry.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A more detailed analysis of the company's financial performance, research and development activities, and competitive landscape would be needed to assess its position relative to industry benchmarks.
• Comparisons could be made to similar-sized biotechnology companies in terms of executive compensation, board composition, and related party transaction policies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a collaborative research and development license agreement with Pharmsynthez.
• The company entered into a clinical trial services agreement with PeriNess Ltd., where Dr. Dmitry Genkin and Mr. Moshe Mizrahy are significant shareholders and directors, respectively.
• The company entered into a Consulting Agreement with Dr. Genkin, Chairman of our Board Directors, to provide consulting services to the Companys DNase-based oncology program.

Stakeholder Impact

• Shareholders are impacted by changes in board composition and executive compensation.
• Employees are impacted by changes in executive leadership and compensation structures.
• The company's relationships with Pharmsynthez and Peri-Ness Technologies could impact its research and development activities.

Next Steps

• Pharmsynthez will determine next steps regarding a gap mitigation strategy for its Epolong registration dossier in Russia.
• The company's definitive proxy statement will be filed later this year.

Key Dates

Keywords

Xenetic Biosciences, Form 10-K/A, directors, executive officers, compensation, corporate governance, audit committee, related party transactions, Sarbanes-Oxley Act, Marcum LLP